Press release
Eosinophilic Asthma Pipeline 2025: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | Lanier Biotherapeutics, Bio-Thera Solutions, Kinaset Therapeutics, CSPC ZhongQi Pharma
"Eosinophilic Asthma Pipeline Insight, 2025 [https://www.delveinsight.com/sample-request/eosinophilic-asthma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Eosinophilic Asthma Market.
The Eosinophilic Asthma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Eosinophilic Asthma Pipeline Report:
*
Companies across the globe are diligently working toward developing novel Eosinophilic Asthma treatment therapies with a considerable amount of success over the years.
*
Eosinophilic Asthma companies working in the treatment market are Lanier Biotherapeutics, Bio-Thera Solutions, Kinaset Therapeutics, CSPC ZhongQi Pharmaceutical Technology, Oneness Biotech Co., Ltd., Chia Tai Tianqing Pharmaceutical Group, AB Science, GlaxoSmithKline, and others, are developing therapies for the Eosinophilic Asthma treatment
*
Emerging Eosinophilic Asthma therapies in the different phases of clinical trials are- LNR 125.38, BAT2606, KN-002, CM326, FB 704A, TQC2731, Masitinib, GSK3511294, and others are expected to have a significant impact on the Eosinophilic Asthma market in the coming years.
*
In May 2025, AstraZeneca's triple-combination therapy, Breztri Aerosphere (budesonide/glycopyrronium/formoterol fumarate), achieved its primary goals in two Phase III clinical trials for Eosinophilic Asthma. In the KALOS (NCT04609878) and LOGOS (NCT04609904) studies, Breztri demonstrated statistically significant and clinically meaningful improvements in lung function compared to dual-combination ICS/LABA treatments. These randomized, double-blind trials involved a total of 4,434 patients with uncontrolled Eosinophilic Asthma, aiming to evaluate Breztri as a potential therapeutic option.
*
In March 2025, Connect Biopharma Holdings Limited (Nasdaq: CNTB), a clinical-stage biopharmaceutical company focused on advancing treatments for Eosinophilic Asthma and Chronic Obstructive Pulmonary Disease (COPD), announced encouraging findings from its global Phase 2 trial of rademikibart. Published in the American Journal of Respiratory and Critical Care Medicine (AJRCCM), the results highlight the potential of rademikibart as an innovative biologic therapy for individuals with moderate-to-severe uncontrolled Eosinophilic Asthma linked to Type 2 inflammation. The study reported a rapid onset of action, consistent improvements in lung function (FEV1), and notable reductions in the annual rate of Eosinophilic Asthma exacerbations.
*
In October 2024, AstraZeneca announced positive top-line results from its Phase IIIb BATURA trial, demonstrating that AIRSUPRA Registered (a combination of albuterol and budesonide) successfully met its primary endpoint. When used as an as-needed rescue therapy, AIRSUPRA Registered significantly lowered the risk of severe Eosinophilic Asthma exacerbations compared to albuterol alone. The study involved patients with intermittent or mild persistent Eosinophilic Asthma, including those using short-acting beta2-agonists (SABA), low-dose inhaled corticosteroids (ICS), or leukotriene receptor antagonists (LTRA) for maintenance therapy.
*
In September 2024, Kinaset Therapeutics presented two oral sessions and a late-breaking poster at the 2024 European Respiratory Society (ERS) Congress, highlighting the potential of its lead clinical asset, frevecitinib (KN-002), as a promising treatment for individuals with moderate to severe Eosinophilic Asthma and chronic obstructive pulmonary disease (COPD).
Eosinophilic Asthma Overview
Eosinophilic Asthma is a severe type of asthma characterized by high levels of eosinophils (a type of white blood cell) in the airways, leading to chronic inflammation. This condition often causes frequent asthma attacks, breathing difficulties, wheezing, and reduced lung function. It is usually harder to control with standard asthma treatments, and patients may require targeted biologic therapies that specifically reduce eosinophil activity.
Get a Free Sample PDF Report to know more about Eosinophilic Asthma Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/eosinophilic-asthma-pipeline-insight [https://www.delveinsight.com/report-store/eosinophilic-asthma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Emerging Eosinophilic Asthma Drugs Under Different Phases of Clinical Development Include:
*
LNR 125.38: Lanier Biotherapeutics
*
BAT2606: Bio-Thera Solutions
*
KN-002: Kinaset Therapeutics
*
CM326: CSPC ZhongQi Pharmaceutical Technology
*
FB 704A: Oneness Biotech Co., Ltd.
*
TQC2731: Chia Tai Tianqing Pharmaceutical Group
*
Masitinib: AB Science
*
GSK3511294: GlaxoSmithKline
Eosinophilic Asthma Pipeline Therapeutics Assessment
*
Eosinophilic Asthma Assessment by Product Type
*
Eosinophilic Asthma By Stage and Product Type
*
Eosinophilic Asthma Assessment by Route of Administration
*
Eosinophilic Asthma By Stage and Route of Administration
*
Eosinophilic Asthma Assessment by Molecule Type
*
Eosinophilic Asthma by Stage and Molecule Type
DelveInsight's Eosinophilic Asthma Report covers around products under different phases of clinical development like
*
Late-stage products (Phase III)
*
Mid-stage products (Phase II)
*
Early-stage product (Phase I)
*
Pre-clinical and Discovery stage candidates
*
Discontinued & Inactive candidates
*
Route of Administration
Further Eosinophilic Asthma product details are provided in the report. Download the Eosinophilic Asthma pipeline report to learn more about the emerging Eosinophilic Asthma therapies [https://www.delveinsight.com/sample-request/eosinophilic-asthma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Some of the key companies in the Eosinophilic Asthma Therapeutics Market include:
Key companies developing therapies for Eosinophilic Asthma are - Genentech, Inc., GlaxoSmithKline, Kymab, Sanofi, 4D Pharma plc, AstraZeneca, Sinomab, Avalo Therapeutics, Suzhou Connect Biopharmaceuticals, Avillion, Pearl Therapeutics, ARS Pharmaceuticals, Cumberland Pharmaceuticals, and others.
Eosinophilic Asthma Pipeline Analysis:
The Eosinophilic Asthma pipeline report provides insights into
*
The report provides detailed insights about companies that are developing therapies for the treatment of Eosinophilic Asthma with aggregate therapies developed by each company for the same.
*
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Eosinophilic Asthma Treatment.
*
Eosinophilic Asthma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
*
Eosinophilic Asthma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Eosinophilic Asthma market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Eosinophilic Asthma drugs and therapies [https://www.delveinsight.com/sample-request/eosinophilic-asthma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Eosinophilic Asthma Pipeline Market Drivers
*
Increase in the prevalence of Eosinophilic Asthma, development of new and innovative treatment options for severe Eosinophilic Asthma are some of the important factors that are fueling the Eosinophilic Asthma Market.
Eosinophilic Asthma Pipeline Market Barriers
*
However, high cost of Eosinophilic Asthma medications, poor adherence to treatment, limited efficacy of existing treatments and other factors are creating obstacles in the Eosinophilic Asthma Market growth.
Scope of Eosinophilic Asthma Pipeline Drug Insight
*
Coverage: Global
*
Key Eosinophilic Asthma Companies: Lanier Biotherapeutics, Bio-Thera Solutions, Kinaset Therapeutics, CSPC ZhongQi Pharmaceutical Technology, Oneness Biotech Co., Ltd., Chia Tai Tianqing Pharmaceutical Group, AB Science, GlaxoSmithKline, and others
*
Key Eosinophilic Asthma Therapies: LNR 125.38, BAT2606, KN-002, CM326, FB 704A, TQC2731, Masitinib, GSK3511294, and others
*
Eosinophilic Asthma Therapeutic Assessment: Eosinophilic Asthma current marketed and Eosinophilic Asthma emerging therapies
*
Eosinophilic Asthma Market Dynamics: Eosinophilic Asthma market drivers and Eosinophilic Asthma market barriers
Request for Sample PDF Report for Eosinophilic Asthma Pipeline Assessment and clinical trials [https://www.delveinsight.com/sample-request/eosinophilic-asthma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Table of Contents
1. Eosinophilic Asthma Report Introduction
2. Eosinophilic Asthma Executive Summary
3. Eosinophilic Asthma Overview
4. Eosinophilic Asthma- Analytical Perspective In-depth Commercial Assessment
5. Eosinophilic Asthma Pipeline Therapeutics
6. Eosinophilic Asthma Late Stage Products (Phase II/III)
7. Eosinophilic Asthma Mid Stage Products (Phase II)
8. Eosinophilic Asthma Early Stage Products (Phase I)
9. Eosinophilic Asthma Preclinical Stage Products
10. Eosinophilic Asthma Therapeutics Assessment
11. Eosinophilic Asthma Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Eosinophilic Asthma Key Companies
14. Eosinophilic Asthma Key Products
15. Eosinophilic Asthma Unmet Needs
16 . Eosinophilic Asthma Market Drivers and Barriers
17. Eosinophilic Asthma Future Perspectives and Conclusion
18. Eosinophilic Asthma Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=eosinophilic-asthma-pipeline-2025-therapies-moa-insights-and-key-clinical-trial-updates-by-delveinsight-lanier-biotherapeutics-biothera-solutions-kinaset-therapeutics-cspc-zhongqi-pharma]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Eosinophilic Asthma Pipeline 2025: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | Lanier Biotherapeutics, Bio-Thera Solutions, Kinaset Therapeutics, CSPC ZhongQi Pharma here
News-ID: 4192361 • Views: …
More Releases from ABNewswire
CopperJoint's Odor-Resistant Copper Compression Socks for Women and Men Offer Al …
CopperJoint has launched a powerful update to its best-selling socks: men's and copper compression socks women trust for odor control, seamless comfort, and 15-20 mmHg graduated compression. From office meetings to 12-hour shifts, these socks provide sleek support without bulk. "This is next-level relief and recovery, packed into a sock that looks as sharp as it feels."
NASHVILLE, TN - September 22, 2025 - CopperJoint, a leader in copper-infused wellness wear,…
2025 Trans-Siberian Orchestra Holiday Tour: Cheapest Concert Tickets Online + 10 …
The 2025 Trans-Siberian Orchestra Holiday Tour is set to bring its signature mix of rock, symphony, and holiday magic to arenas nationwide. Fans can find the cheapest TSO tickets online at CapitalCityTickets.com and save even more with promo code CITY10 for an extra 10% off. Whether you're looking for floor seats, front row, or affordable upper-level options, this deal ensures you experience the unforgettable holiday tradition at the best price.
The…
To Close Construction's "Experience Gap," Veteran PE Roman Titov Mentors Next-Ge …
To combat the construction industry's "experience gap," veteran leader Roman Titov, P.E. (formerly of AWS & Jacobs), is mentoring the next generation of engineers. Through his courses at PDH-Pro, Titov shares practical, real-world project management wisdom to prepare future leaders for on-the-job challenges, bridging the gap between textbook theory and reality.
WELLESLEY, Mass. - Sept. 22, 2025 - As a generation of senior construction professionals prepares for retirement, a critical "experience…
Burna Boy Concert Tickets on a Budget: Lowest Prices with CITY10 Discount at Cap …
Catch Burna Boy live without breaking the bank! CapitalCityTickets.com offers the lowest prices on Burna Boy concert tickets. Use promo code CITY10 for extra savings and secure your spot at his electrifying shows. Don't miss out on the Afrobeat sensation-grab affordable tickets today and experience an unforgettable night of music and energy!
Are you a Burna Boy fan itching to catch the Afrobeat king live without draining your wallet? With his…
More Releases for Eosinophilic
Eosinophilic Esophagitis Market to Surge to USD 4.1 Billion by 2034
Eosinophilic Esophagitis (EoE) is a chronic, immune-mediated inflammatory condition of the esophagus, characterized by eosinophil infiltration, difficulty swallowing, food impaction, and chest pain. Once considered rare, EoE has now emerged as one of the most common causes of dysphagia in children and adults, particularly in developed nations. Strong associations with allergic conditions such as asthma, eczema, and food allergies underscore its complex immunological nature.
Download Full PDF Sample Copy of Market…
Eosinophilic Asthma Treatment Market Outlook and Future Projections for 2030
The eosinophilic asthma treatment market represents a dynamic and continually evolving landscape, shaped by changing consumer demands and technological advancements. In this comprehensive report, we provide an in-depth exploration of the market, designed for a wide range of stakeholders including manufacturers, suppliers, distributors, and investors. Our goal is to equip industry participants with essential insights that enable informed decision-making in an ever-changing market environment. This analysis not only examines the…
Severe Eosinophilic Asthma Treatment Market Outlook and Future Projections for 2 …
The severe eosinophilic asthma treatment market represents a dynamic and continually evolving landscape, shaped by changing consumer demands and technological advancements. In this comprehensive report, we provide an in-depth exploration of the market, designed for a wide range of stakeholders including manufacturers, suppliers, distributors, and investors. Our goal is to equip industry participants with essential insights that enable informed decision-making in an ever-changing market environment. This analysis not only examines…
Eosinophilic Esophagitis Pipeline, Clinical Trials Assessment, Emerging Therapie …
DelveInsight's, "Eosinophilic Esophagitis Pipeline Insight" report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in Eosinophilic Esophagitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in Eosinophilic Esophagitis research. Learn more about…
Severe Eosinophilic Asthma Treatment Market Outlook and Future Projections for 2 …
The severe eosinophilic asthma treatment market represents a dynamic and continually evolving landscape, shaped by changing consumer demands and technological advancements. In this comprehensive report, we provide an in-depth exploration of the market, designed for a wide range of stakeholders including manufacturers, suppliers, distributors, and investors. Our goal is to equip industry participants with essential insights that enable informed decision-making in an ever-changing market environment. This analysis not only examines…
Eosinophilic Granulomatosis Treatment Market Size and Overview Upto 2028|
The report comes out as an intelligent and thorough assessment tool as well as a great resource that will help you to secure a position of strength in the global Eosinophilic Granulomatosis Treatment market. It includes Porter's Five Forces and PESTLE analysis to equip your business with critical information and comparative data about the Global Eosinophilic Granulomatosis Treatment Market. We have provided a deep analysis of the vendor landscape to give…
